In respect of the regulatory agencies guidelines (EUDRA, FDA, ICH, …) for cardiovascular drug safety, particularly concerning QT/QTc interval prolongation and proarrhythmic potential for drugs, we can offer:
Continuous safety monitoring (72 Physiogard TM910 Brücker® systems)
These techniques allow an in depth analysis of the cardiovascular effects of drugs, in particular on sympathovagal balance and ventricular repolarization including “thorough QT/QTc studies”. They are very sensitive in seeking the minimal active dose. They can be performed simultaneously with Central Nervous System examinations (wake/sleep EEG, MEG, …) and under various experimental conditions (clinostatism/orthostatism, stress, …).
For further cardiovascular exploration, we can offer:
